Apply on Kit Job: kitjob.ca/job/2fs2te

Helixion Therapeutics is building Elyra — an AI-driven neoantigen discovery engine that converts tumor DNA into ranked neoantigen candidates for personalized mRNA cancer vaccines. DNA in. Vaccine blueprint out. In days.

Our production scorer has been externally validated on the TESLA benchmark (AUC 0.812, outperforming pVACtools), and we're preparing for our first clinical partnerships. We're looking for a Chief Scientific Officer to lead our scientific strategy from computational validation through IND-stage regulatory milestones.

What you’ll own:

The entire scientific trajectory of a personalized cancer vaccine company at its most formative stage. You’ll shape the R&D; roadmap, guide neoantigen scoring model development, design clinical validation studies, build relationships with academic and pharma partners, and lead our regulatory strategy toward first-in-human applications. This is a co-founder-level role with meaningful equity.

What we’re looking for:

A scientist with deep expertise in neoantigen biology and cancer immunology who can bridge computational prediction with clinical translation. Specifically:

- PhD in immunology, oncology, computational biology, or a related field




- Experience with IND-stage regulatory processes or clinical trial design for cancer vaccines
- Familiarity with MHC binding prediction, immunogenicity scoring, or related computational tools (pVACseq, MHCflurry, NetMHCpan)
- Ability to evaluate and improve ML-based scoring models for neoantigen prioritization

Nice to have:

- Experience with mRNA vaccine platforms
- Track record of translating computational or preclinical work into clinical programs
- Existing relationships with oncology KOLs, clinical sites, or pharma partners
- Regulatory experience with FDA or Health Canada

About Helixion:

Founded by Sean Clark (CEO of Hut 8 Mining, TSX-listed; founder of First Block Capital) and Marc van der Chijs (co-founder of Tudou.com, NASDAQ-listed, sold to Alibaba). We’re pre-seed, preparing for a TSXV/CSE listing, and believe cancer vaccine design is fundamentally a software problem — fast, reproducible, scalable, affordable.

Headquartered in Vancouver, BC. Market-competitive salary, significant equity, and the chance to shape a company from the ground up.

#J-18808-Ljbffr

Apply on Kit Job: kitjob.ca/job/2fs2te

📌 Chief Scientific Officer (Vancouver)
🏢 Helixion Therapeutics
📍 Vancouver